Table 2.

Predicted PK parameters^a for CT-P13 s.c. and CT-P13 i.v. (PK population^b)

Parameter Week	CT-P13 s.c. (n = 166)		CT-P13 i.v. (n = 174)
	n	Mean (CV%)	n	Mean (CV%)
AUCτ, h·µg/ml
22	162	5311.5 (45.6)	165	14,156.9 (46.3)
24	160	5187.9 (45.3)	N/A	N/A
26	161	5273.1 (47.3)	N/A	N/A
28	160	5157.2 (46.6)	N/A	N/A
AUCW22–30, h·µg/ml
22	162	20,926.6 (45.4)	N/A	N/A
Cmax, µg/ml
22	162	17.74 (40.87)	165	71.60 (16.89)
24	160	17.62 (40.73)	N/A	N/A
26	161	17.63 (41.10)	N/A	N/A
28	160	17.54 (40.63)	N/A	N/A
Ctrough, µg/ml
22	162	12.19 (54.25)	165	1.49 (168.41)
24	160	12.30 (53.96)	N/A	N/A
26	161	12.18 (53.42)	N/A	N/A
28	160	12.17 (54.58)	N/A	N/A

^aPK parameters (AUC_τ, C_max and C_trough) were estimated from population PK modelling, and AUC_W22–30 for the CT-P13 s.c. arm was estimated due to the different dosing interval of s.c. and i.v. administration [every 2 weeks (W6–28) and every 8 weeks (W6, W14 and W22), respectively]. ^bAnalysed according to actual treatment received. AUC_τ, model-predicted area under the concentration–time curve at steady-state between W22 and W30; AUC_W22–30, model-predicted area under the concentration–time curve due to different dosing interval of s.c. and i.v. administration using population PK model; C_max, model-predicted maximum serum concentration after study drug administration; C_trough, model-predicted trough serum concentration; CV%, per cent coefficient of variation; N/A, not applicable; PK, pharmacokinetic; W, week.